Shift Bioscience, a biotech company using an AI powered virtual cell to fight age-related diseases, has appointed Jill Reckless, Ph.D, as Translation Advisor and Laurence Reid, Ph.D., as Non-Executive Director. In these roles, Reckless and Reid will guide Shift in building a robust product translation and business development strategy.

Following the Company’s recent expansion into North America, these appointments aim to strengthen Shift’s position, providing expert guidance and strategic insights to leverage the Company’s AI powered virtual cell platform and accelerate its growth plans.

Dr. Jill Reckless, Translation Advisor

As Translation Advisor, Reckless will work closely with Shift’s therapeutic translation team, to guide indication selection based on proof-of-concept data and therapeutic modalities suited to rejuvenation biology.

Reckless brings more than 20 years of expertise in translational biology, having successfully led drug discovery programs across a broad range of therapeutic indications and therapeutic modalities. She is currently the CEO and Co-founder of RxCelerate, where she has supported the company from start-up to establishing it as a leading provider of drug discovery and development services. She has worked closely with companies to design and execute complex therapeutic discovery pipelines.

Reckless holds a Ph.D. from the National Heart and Lung Institute at Imperial College, London, and spent over a decade as an academic as part of the Department of Medicine at University of Cambridge.

Dr. Laurence Reid, Non-Executive Director

In his role as non-Executive Director, Reid will support the design and implementation of an effective business development framework, supporting company growth and harnessing advances in proof-of-concept data by strengthening product and commercial strategy.

Reid is an accomplished biotech entrepreneur, serving multiple C-Suite roles throughout his 30 years of experience in the pharma and biotech industries, specializing in strategic planning to advance new discovery platforms for clinical translation and financing.

He has held several executive positions within the industry, serving as CEO at Decibel Therapeutics (acquired by Regeneron Pharmaceuticals) and Warp Drive Bio (merged with Revolution Medicines), as well as senior executive and business development roles at Alnylam Pharmaceuticals and Millennium Pharmaceuticals. Reid sits on the Board of several companies, including KalVista Pharmaceuticals, Garuda Therapeutics and Broken String Biosciences.

He holds a Ph.D. in Biochemistry from King’s College, London.